<DOC>
	<DOCNO>NCT00169000</DOCNO>
	<brief_summary>The combination capecitabine docetaxel give treat several different type cancer . Capecitabine usually give mouth 14 day , docetaxel give IV first day capecitabine . The effect change schedule combination docetaxel capecitabine examine human breast cancer cell . A capecitabine by-product give orally breast cancer-bearing animal 14 consecutive day . Docetaxel give IV variety time day 1 15 . The great reduction volume cancer see animal treat docetaxel day 6 10 . In two breast cancer model , maximal degree delay growth tumor achieve animal treat docetaxel day 8 14 day course capecitabine . The extent tumor response explain change tumor level enzyme thymidine phosphorylase , think mechanism behind interaction capecitabine docetaxel . In breast cancer cell , capecitabine increase level protein promote death cancer cell , inhibits level protein block death cancer cell . Our hypothesis capecitabine docetaxel interact , capecitabine primes pro-death machinery cell increase ratio death-promoting protein death-inhibiting protein . Cells susceptible kill docetaxel pro-death machinery activate capecitabine . This safety study find high dose capecitabine give safely 14 day , combination docetaxel give fix dose day 8 . Once dose capecitabine determine , additional nine patient tumor biopsied treat dose , level capecitabine , byproduct , docetaxel measure bloodstream . Biopsies tumor also take docetaxel give , level pro-death anti-death protein measure .</brief_summary>
	<brief_title>Safety Study New Schedule Capecitabine Docetaxel Treat Cancers</brief_title>
	<detailed_description>This phase I study use accelerate titration design determine maximum tolerate dose ( MTD ) capecitabine give orally BID schedule day 1-14 , combination docetaxel give fix dose 75 mg/m2 IV day 8 . Once MTD capecitabine determine , additional nine patient accessible tumor treat MTD . Pharmacokinetics plasma capecitabine , 5-FU , 5'-deoxy-5-fluorouridine , docetaxel assayed nine patient , tumor biopsy take assess Bax : Bcl-2 ratio Bcl-2 phosphorylation several time point . The primary aim study determine maximum tolerate dose dose limit toxicity capecitabine give fix dose docetaxel day 8 21 day schedule . Secondary aim include assessment pharmacokinetics capecitabine docetaxel schedule , determination intratumoral Bax : Bcl-2 , Bcl-2 phosphorylation , DPD expression , correlation clinical toxicity antitumor response .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients histologically cytologically proven metastatic solid tumor . Patients measurable disease evaluable bone lesion undergo biopsy . Patients treat within additional cohort MTD metastatic breast cancer site disease amenable percutaneous FNA must willing undergo serial FNA biopsy primary tumor . Age &gt; 18 year . Life expectancy least 6 month . ECOG performance status 02 . Adequate hematologic , hepatic , renal function Patients must intact upper gastrointestinal tract , able swallow tablet , malabsorption syndrome . No significant uncontrolled infectious cardiovascular disease , myocardial infarction within prior 12 month . No prior organ allograft . No prior treatment capecitabine docetaxel . No prior unanticipated severe reaction fluoropyrimidine therapy know hypersensitivity 5fluorouracil . No concurrent antacid therapy allow . No significant medical/surgical disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>capecitabine</keyword>
	<keyword>docetaxel</keyword>
	<keyword>pharmacokinetic/pharmacodynamic</keyword>
	<keyword>bcl-2</keyword>
	<keyword>bax</keyword>
</DOC>